Control of hepatic gluconeogenesis by the promyelocytic leukemia zinc finger protein

Mol Endocrinol. 2014 Dec;28(12):1987-98. doi: 10.1210/me.2014-1164.

Abstract

The promyelocytic leukemia zinc finger (PLZF) protein is involved in major biological processes including energy metabolism, although its role remains unknown. In this study, we demonstrated that hepatic PLZF expression was induced in fasted or diabetic mice. PLZF promoted gluconeogenic gene expression and hepatic glucose output, leading to hyperglycemia. In contrast, hepatic PLZF knockdown improved glucose homeostasis in db/db mice. Mechanistically, peroxisome proliferator-activated receptor γ coactivator 1α and the glucocorticoid receptor synergistically activated PLZF expression. We conclude that PLZF is a critical regulator of hepatic gluconeogenesis. PLZF manipulation may benefit the treatment of metabolic diseases associated with gluconeogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Cells, Cultured
  • Chromatin Immunoprecipitation
  • Gluconeogenesis / genetics
  • Gluconeogenesis / physiology*
  • Glucose Tolerance Test
  • Hyperglycemia / genetics
  • Hyperglycemia / therapy
  • Immunoprecipitation
  • Kruppel-Like Transcription Factors / genetics
  • Kruppel-Like Transcription Factors / metabolism*
  • Liver / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Promyelocytic Leukemia Zinc Finger Protein

Substances

  • Kruppel-Like Transcription Factors
  • Promyelocytic Leukemia Zinc Finger Protein
  • ZBTB16 protein, human

Grants and funding

This work was supported by grants from the National Basic Research Program of China (973 Program) (2012CB947600 and 2013CB911600), the National Natural Science Foundation of China (31422028, 31171137, 31271261, and 31401009), the Program for the Top Young Talents by the Organization Department of the CPC Central Committee, the Science Fund for Distinguished Young Scholars of Jiangsu Province (BK20140041), the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine (Nanjing Medical University), and the Priority Academic Program Development of Jiangsu Higher Education Institutions.